×
About 24,883 results

ALLMedicine™ Diabetic Retinopathy Center

Research & Reviews  11,891 results

Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflib...
https://doi.org/10.1001/jamaophthalmol.2021.1110
JAMA Ophthalmology; Glassman AR, Beaulieu WT et. al.

May 6th, 2021 - Although there were no differences in mean visual acuity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic ret...

Diabetic retinal neurodegeneration as a form of diabetic retinopathy.
https://doi.org/10.1007/s10792-021-01864-4 10.2337/dc15-2171 10.1186/s40662-015-0026-2 10.1016/j.diabres.2018.02.023 10.1097/APO.0000000000000267 10.3109/08820539909069543 10.1001/archopht.1985.01050010055018 10.14712/18059694.2019.156 10.1172/jci.insight.93751 10.2337/db05-1635 10.1007/s11892-012-0284-5 10.1016/j.biocel.2013.03.002 10.1155/2016/9508541 10.2337/diacare.26.9.2653 10.1007/978-1-4614-3209-8_84 10.1167/iovs.14-15167 10.1007/s00125-017-4435-8 10.2337/db10-0454 10.2337/db08-0325 10.2337/diabetes.55.01.06.db05-0186 10.1136/bjo.79.4.362 10.1016/S0161-6420(03)00475-5 10.1167/iovs.08-3260 10.1007/978-1-4614-4711-5_3 10.1111/1753-0407.12622 10.3390/nu9050437 10.1001/archopht.126.12.1707 10.1056/NEJMra1005073 10.1136/bjophthalmol-2012-302005 10.1016/j.tem.2013.09.005 10.2337/dc07-0332 10.1007/s00125-009-1548-8 10.2337/dc16-2641 10.1172/JCI2425 10.1111/j.1582-4934.2008.00402.x 10.2174/1570159X14666160614095559 10.1080/02713680600987674 10.1167/iovs.07-0683 10.1167/iovs.05-1376 10.1007/BF03401589 10.1007/s00125-003-1177-6 10.1167/iovs.04-0247 10.1007/s00125-017-4381-5 10.1167/iovs.16-19859 10.1111/j.1460-9568.2008.06322.x 10.1007/s00125-002-0818-5 10.1136/bjo.85.10.1252 10.1167/iovs.18-26359 10.1016/j.neulet.2013.12.071 10.1038/s41598-017-09743-8 10.1111/j.1469-7580.2006.00671.x 10.2337/diabetes.47.3.445 10.1007/s00417-006-0489-x 10.1001/archopht.118.10.1393 10.4103/ijo.IJO_400_19 10.1007/BF00400342 10.1007/BF00155037 10.2337/diacare.13.4.412 10.1007/BF00400947 10.1016/S0002-9394(14)74550-7 10.1016/S1350-9462(97)00005-0 10.1007/BF00152764 10.1167/iovs.03-1080 10.1167/iovs.03-0424 10.1136/bjo.85.4.414 10.1167/iovs.07-1157 10.1167/iovs.03-1101 10.1001/archopht.122.12.1809 10.1016/j.preteyeres.2004.07.002 10.1167/iovs.10-5960 10.1007/s10633-011-9298-6 10.1038/s41433-020-1020-z 10.1167/iovs.08-3143 10.1167/iovs.09-5041 10.1167/iovs.11-8997 10.4103/0301-4738.136234 10.1167/iovs.15-17334 10.1186/s12886-016-0186-4 10.2337/db16-1453 10.3928/23258160-20160707-03 10.1159/000328979 10.1167/iovs.04-0860 10.1038/nrmicro2070 10.1038/cddis.2012.86 10.1001/archophthalmol.2007.65 10.4103/0975-3583.83035 10.1155/2016/8976945 10.2337/diabetes.54.5.1559 10.1167/iovs.05-0118 10.1002/glia.20610 10.1017/S0952523800173122 10.2337/db11-0026 10.1076/ocii.10.1.27.10328 10.1038/sj.eye.6700207 10.1016/j.ajo.2006.02.016 10.1136/bjo.2007.132308 10.1073/pnas.1314575110 10.1007/s00125-014-3194-z 10.1016/j.bbrc.2013.07.066 10.1016/j.mvr.2013.01.002 10.1111/j.1471-4159.1985.tb04008.x 10.1023/A:1011098829378 10.1167/iovs.15-17999 10.1006/exer.2000.0840 10.1016/S0197-0186(00)00112-1 10.1001/archopht.1957.00940010205006 10.1001/archopht.1997.01100160331011 10.1155/2007/36150 10.1155/2016/2701526 10.1371/journal.pone.0030343 10.1152/ajpcell.00426.2011 10.2337/diabetes.54.6.1615 10.1155/2016/3164734 10.1038/78774 10.1016/j.preteyeres.2006.05.003 10.1523/JNEUROSCI.22-21-09228.2002 10.1159/000088637 10.1371/journal.pone.0003554 10.1073/pnas.0813061106 10.1016/S0306-4522(01)00154-3 10.2353/ajpath.2007.061237 10.1002/path.2611 10.2174/092986711794088317 10.1124/jpet.109.157941 10.1007/s00125-005-1951-8 10.1056/NEJMcibr022629 10.2337/dc06-0556 10.1167/iovs.09-3544 10.2174/1874364101307010004 10.1523/JNEUROSCI.20-02-00722.2000 10.1167/iovs.04-1339 10.1074/jbc.M104738200 10.1136/bjo.81.3.228 10.1172/JCI116877 10.3109/02713689408999886 10.1016/j.preteyeres.2004.05.002 10.1038/nrn1176 10.1007/s00125-002-1013-4 10.1016/j.yjmcc.2004.04.007 10.1016/j.exer.2005.10.016 10.4172/2155-9570.1000483 10.1080/15438600303729 10.1038/383716a0 10.1007/s12640-009-9054-9 10.1523/JNEUROSCI.06-10-03031.1986 10.2337/diabetes.53.9.2412 10.2337/diacare.25.12.2282 10.2337/dc06-1345 10.1016/j.exer.2006.09.003 10.1523/JNEUROSCI.18-12-04511.1998 10.2174/0929867324666170407141955 10.1002/glia.20680 10.2337/db07-1281 10.2337/db09-0166 10.1002/dmrr.1007 10.3892/mmr.2013.1433 10.1167/iovs.07-0427 10.1111/1440-1681.12326 10.4149/gpb_2012_039 10.1016/j.exer.2014.06.009 10.1007/s00417-010-1362-5 10.1006/nbdi.1999.0263 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.0.CO;2-M 10.2337/diabetes.55.04.06.db05-0744 10.1167/iovs.09-5032 10.1167/iovs.05-0392 10.3390/jcm8030339 10.1016/S1734-1140(12)70948-9 10.1089/jmf.2011.0135 10.1167/iovs.12-10647 10.3109/01913123.2015.1045664 10.1007/s11064-013-1058-4 10.1590/1414-431x20154583 10.1073/pnas.1522014113 10.1371/journal.pone.0097970 10.2337/db14-1030 10.1113/jphysiol.2008.156695 10.1136/bjo.86.7.725 10.1167/iovs.04-0842 10.1167/iovs.04-0405 10.1167/iovs.10-5931 10.1001/archopht.1987.01060060096041 10.2337/db18-0682 10.4103/0301-4738.178145 10.1159/000310117 10.3390/s130100334 10.1038/s41598-019-52354-8 10.1016/j.ajo.2019.09.010 10.1016/j.ajo.2020.02.028
International Ophthalmology; Soni D, Sagar P et. al.

May 6th, 2021 - To review the evidence supporting diabetic retinal neurodegeneration (DRN) as a form of diabetic retinopathy. Review of literature. DRN is recognized to be a part of retinopathy in patients with diabetes mellitus (DM), in addition to the well-esta...

Correlation of sectoral choroidal vascularity with angiographic leakage in central sero...
https://doi.org/10.1177/11206721211013653
European Journal of Ophthalmology; Singh SR, Beale O et. al.

May 5th, 2021 - To correlate sectoral choroidal vascularity with angiographic leakage in eyes with central serous chorioretinopathy (CSCR). This was a retrospective, cross-sectional study including patients with active CSCR. Multimodal imaging including fundus fl...

Activation of Insulin-Like Growth Factor-2 Ameliorates Retinal Cell Damage and Exerts P...
https://doi.org/10.1159/000515662
Neuroimmunomodulation Zhao Y, Xiong Z et. al.

May 5th, 2021 - The major event in the development of diabetes-related blindness and vision impairment is the onset of retinal cell damage. Overall awareness of insulin-like growth factor-2 (IGF2) mechanisms emphasizes its protective behavior in retinal cells tha...

Dysregulation of miR-374a is involved in the progression of diabetic retinopathy and re...
https://doi.org/10.1080/08164622.2021.1913043
Clinical & Experimental Optometry; Wang Z, Zhang X et. al.

May 4th, 2021 - Clinical relevance: microRNAs (miRNAs) have been reported to be involved in the progression of various diseases.Background: This study evaluated the expression and clinical value of miR-374a in diabetic retinopathy (DR) patients and analysed the e...

see more →

Guidelines  15 results

Diabetic Retinopathy Preferred Practice Pattern®.
https://doi.org/10.1016/j.ophtha.2019.09.025
Ophthalmology Flaxel CJ, Adelman RA et. al.

Nov 23rd, 2019 - Diabetic Retinopathy Preferred Practice Pattern®.|2019|Flaxel CJ,Adelman RA,Bailey ST,Fawzi A,Lim JI,|standards,diagnosis,epidemiology,therapy,organization & administration,standards,

Randomized Controlled Phase 2a Study of RPh201 in Previous Nonarteritic Anterior Ischemic Optic Neuropathy
https://journals.lww.com/jneuro-ophthalmology/Abstract/publishahead/Randomized_Controlled_Phase_2a_Study_of_RPh201_in.99147.aspx
Rath,E.,et al

Jul 21st, 2019 - Background: No proven treatment exists for nonarteritic anterior ischemic optic neuropathy (NAION), either in the acute or late phase. Objective: To assess safety and changes in visual function and structure after RPh201/placebo treatment in part...

FDA Approves Eylea (Aflibercept) Injection For Diabetic Retinopathy
https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-diabetic-retinopathy

May 12th, 2019 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness....

Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice gui...
https://doi.org/10.1016/j.jcjo.2017.09.027
Canadian Journal of Ophthalmology. Journal Canadien D'oph... Hooper P, Boucher MC et. al.

Oct 27th, 2017 - Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.|2017|Hooper P,Boucher MC,Cruess A,Dawson KG,Delpero W,|epidemiology,epidemiology,diagnosis,epidemiology,ther...

Diabetes Eye Health: A guide for health professionals - IDF Guideline
https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/76:diabetes-eye-health-a-guide-for-health-professionals-en.html
International Diabetes Federation

Dec 31st, 2014 - The guide was developed by the International Diabetes Federation and the Fred Hollows Foundation, and builds upon the ICO Guidelines for Diabetic Eye Care. This guide encourages and facilitates good diabetes management, early diagnosis and treatme.

see more →

Drugs  4 results see all →

Clinicaltrials.gov  12,395 results

Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflib...
https://doi.org/10.1001/jamaophthalmol.2021.1110
JAMA Ophthalmology; Glassman AR, Beaulieu WT et. al.

May 6th, 2021 - Although there were no differences in mean visual acuity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic ret...

Diabetic retinal neurodegeneration as a form of diabetic retinopathy.
https://doi.org/10.1007/s10792-021-01864-4 10.2337/dc15-2171 10.1186/s40662-015-0026-2 10.1016/j.diabres.2018.02.023 10.1097/APO.0000000000000267 10.3109/08820539909069543 10.1001/archopht.1985.01050010055018 10.14712/18059694.2019.156 10.1172/jci.insight.93751 10.2337/db05-1635 10.1007/s11892-012-0284-5 10.1016/j.biocel.2013.03.002 10.1155/2016/9508541 10.2337/diacare.26.9.2653 10.1007/978-1-4614-3209-8_84 10.1167/iovs.14-15167 10.1007/s00125-017-4435-8 10.2337/db10-0454 10.2337/db08-0325 10.2337/diabetes.55.01.06.db05-0186 10.1136/bjo.79.4.362 10.1016/S0161-6420(03)00475-5 10.1167/iovs.08-3260 10.1007/978-1-4614-4711-5_3 10.1111/1753-0407.12622 10.3390/nu9050437 10.1001/archopht.126.12.1707 10.1056/NEJMra1005073 10.1136/bjophthalmol-2012-302005 10.1016/j.tem.2013.09.005 10.2337/dc07-0332 10.1007/s00125-009-1548-8 10.2337/dc16-2641 10.1172/JCI2425 10.1111/j.1582-4934.2008.00402.x 10.2174/1570159X14666160614095559 10.1080/02713680600987674 10.1167/iovs.07-0683 10.1167/iovs.05-1376 10.1007/BF03401589 10.1007/s00125-003-1177-6 10.1167/iovs.04-0247 10.1007/s00125-017-4381-5 10.1167/iovs.16-19859 10.1111/j.1460-9568.2008.06322.x 10.1007/s00125-002-0818-5 10.1136/bjo.85.10.1252 10.1167/iovs.18-26359 10.1016/j.neulet.2013.12.071 10.1038/s41598-017-09743-8 10.1111/j.1469-7580.2006.00671.x 10.2337/diabetes.47.3.445 10.1007/s00417-006-0489-x 10.1001/archopht.118.10.1393 10.4103/ijo.IJO_400_19 10.1007/BF00400342 10.1007/BF00155037 10.2337/diacare.13.4.412 10.1007/BF00400947 10.1016/S0002-9394(14)74550-7 10.1016/S1350-9462(97)00005-0 10.1007/BF00152764 10.1167/iovs.03-1080 10.1167/iovs.03-0424 10.1136/bjo.85.4.414 10.1167/iovs.07-1157 10.1167/iovs.03-1101 10.1001/archopht.122.12.1809 10.1016/j.preteyeres.2004.07.002 10.1167/iovs.10-5960 10.1007/s10633-011-9298-6 10.1038/s41433-020-1020-z 10.1167/iovs.08-3143 10.1167/iovs.09-5041 10.1167/iovs.11-8997 10.4103/0301-4738.136234 10.1167/iovs.15-17334 10.1186/s12886-016-0186-4 10.2337/db16-1453 10.3928/23258160-20160707-03 10.1159/000328979 10.1167/iovs.04-0860 10.1038/nrmicro2070 10.1038/cddis.2012.86 10.1001/archophthalmol.2007.65 10.4103/0975-3583.83035 10.1155/2016/8976945 10.2337/diabetes.54.5.1559 10.1167/iovs.05-0118 10.1002/glia.20610 10.1017/S0952523800173122 10.2337/db11-0026 10.1076/ocii.10.1.27.10328 10.1038/sj.eye.6700207 10.1016/j.ajo.2006.02.016 10.1136/bjo.2007.132308 10.1073/pnas.1314575110 10.1007/s00125-014-3194-z 10.1016/j.bbrc.2013.07.066 10.1016/j.mvr.2013.01.002 10.1111/j.1471-4159.1985.tb04008.x 10.1023/A:1011098829378 10.1167/iovs.15-17999 10.1006/exer.2000.0840 10.1016/S0197-0186(00)00112-1 10.1001/archopht.1957.00940010205006 10.1001/archopht.1997.01100160331011 10.1155/2007/36150 10.1155/2016/2701526 10.1371/journal.pone.0030343 10.1152/ajpcell.00426.2011 10.2337/diabetes.54.6.1615 10.1155/2016/3164734 10.1038/78774 10.1016/j.preteyeres.2006.05.003 10.1523/JNEUROSCI.22-21-09228.2002 10.1159/000088637 10.1371/journal.pone.0003554 10.1073/pnas.0813061106 10.1016/S0306-4522(01)00154-3 10.2353/ajpath.2007.061237 10.1002/path.2611 10.2174/092986711794088317 10.1124/jpet.109.157941 10.1007/s00125-005-1951-8 10.1056/NEJMcibr022629 10.2337/dc06-0556 10.1167/iovs.09-3544 10.2174/1874364101307010004 10.1523/JNEUROSCI.20-02-00722.2000 10.1167/iovs.04-1339 10.1074/jbc.M104738200 10.1136/bjo.81.3.228 10.1172/JCI116877 10.3109/02713689408999886 10.1016/j.preteyeres.2004.05.002 10.1038/nrn1176 10.1007/s00125-002-1013-4 10.1016/j.yjmcc.2004.04.007 10.1016/j.exer.2005.10.016 10.4172/2155-9570.1000483 10.1080/15438600303729 10.1038/383716a0 10.1007/s12640-009-9054-9 10.1523/JNEUROSCI.06-10-03031.1986 10.2337/diabetes.53.9.2412 10.2337/diacare.25.12.2282 10.2337/dc06-1345 10.1016/j.exer.2006.09.003 10.1523/JNEUROSCI.18-12-04511.1998 10.2174/0929867324666170407141955 10.1002/glia.20680 10.2337/db07-1281 10.2337/db09-0166 10.1002/dmrr.1007 10.3892/mmr.2013.1433 10.1167/iovs.07-0427 10.1111/1440-1681.12326 10.4149/gpb_2012_039 10.1016/j.exer.2014.06.009 10.1007/s00417-010-1362-5 10.1006/nbdi.1999.0263 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.0.CO;2-M 10.2337/diabetes.55.04.06.db05-0744 10.1167/iovs.09-5032 10.1167/iovs.05-0392 10.3390/jcm8030339 10.1016/S1734-1140(12)70948-9 10.1089/jmf.2011.0135 10.1167/iovs.12-10647 10.3109/01913123.2015.1045664 10.1007/s11064-013-1058-4 10.1590/1414-431x20154583 10.1073/pnas.1522014113 10.1371/journal.pone.0097970 10.2337/db14-1030 10.1113/jphysiol.2008.156695 10.1136/bjo.86.7.725 10.1167/iovs.04-0842 10.1167/iovs.04-0405 10.1167/iovs.10-5931 10.1001/archopht.1987.01060060096041 10.2337/db18-0682 10.4103/0301-4738.178145 10.1159/000310117 10.3390/s130100334 10.1038/s41598-019-52354-8 10.1016/j.ajo.2019.09.010 10.1016/j.ajo.2020.02.028
International Ophthalmology; Soni D, Sagar P et. al.

May 6th, 2021 - To review the evidence supporting diabetic retinal neurodegeneration (DRN) as a form of diabetic retinopathy. Review of literature. DRN is recognized to be a part of retinopathy in patients with diabetes mellitus (DM), in addition to the well-esta...

Correlation of sectoral choroidal vascularity with angiographic leakage in central sero...
https://doi.org/10.1177/11206721211013653
European Journal of Ophthalmology; Singh SR, Beale O et. al.

May 5th, 2021 - To correlate sectoral choroidal vascularity with angiographic leakage in eyes with central serous chorioretinopathy (CSCR). This was a retrospective, cross-sectional study including patients with active CSCR. Multimodal imaging including fundus fl...

Activation of Insulin-Like Growth Factor-2 Ameliorates Retinal Cell Damage and Exerts P...
https://doi.org/10.1159/000515662
Neuroimmunomodulation Zhao Y, Xiong Z et. al.

May 5th, 2021 - The major event in the development of diabetes-related blindness and vision impairment is the onset of retinal cell damage. Overall awareness of insulin-like growth factor-2 (IGF2) mechanisms emphasizes its protective behavior in retinal cells tha...

Dysregulation of miR-374a is involved in the progression of diabetic retinopathy and re...
https://doi.org/10.1080/08164622.2021.1913043
Clinical & Experimental Optometry; Wang Z, Zhang X et. al.

May 4th, 2021 - Clinical relevance: microRNAs (miRNAs) have been reported to be involved in the progression of various diseases.Background: This study evaluated the expression and clinical value of miR-374a in diabetic retinopathy (DR) patients and analysed the e...

see more →

News  559 results

Aflibercept Won't Help Vision in Early Diabetic Retinopathy
https://www.medscape.com/viewarticle/948441

Mar 30th, 2021 - Intravitreal injections with aflibercept (Eylea) don't improve the visual acuity of people with nonproliferative diabetic retinopathy (NPDR), researchers say. The treatments do reduce the risk for center-involved diabetic macular edema and prolife...

Bariatric Surgery May Curb Diabetic Eye Disease Incidence but Worsen Existing Retinopathy
https://www.medscape.com/viewarticle/944590

Jan 24th, 2021 - NEW YORK (Reuters Health) - Bariatric surgery was associated with fewer cases of diabetic retinopathy (DR), but early worsening was more severe in patients who already had the condition, a systematic review and meta-analysis reveals. "There are he...

Surgery Equals Drug Treatment for Bleeding in Diabetic Retinopathy
https://www.medscape.com/viewarticle/943374

Dec 29th, 2020 - In the treatment of vitreous hemorrhage from proliferative diabetic retinopathy, intraocular injection with anti–vascular endothelial growth factor (VEGF) shows similar efficacy to that of vitrectomy with photocoagulation; however, patients common...

Diabetic Retinopathy May Predict Greater Risk of COVID-19 Severity
https://www.medscape.com/viewarticle/941780

Nov 30th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Risk of intubation for COVID-19 in very sick hospitalized patients was increased over fivefold in those with diabetic retinopathy compared to thos...

Impact of Bariatric Surgery on Microvascular Complications of Type 2 Diabetes
https://www.medscape.com/viewarticle/940069

Oct 29th, 2020 - Takeaway Bariatric surgery was associated with improvement in measures of diabetic neuropathy and diabetic kidney disease but not diabetic retinopathy in obese patients with type 2 diabetes (T2D).

see more →

Patient Education  19 results see all →